Bibliometric analysis of SGLT2 inhibitor treatment for diabetic kidney disease
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors show significant renoprotective potential for diabetic kidney disease, while comprehensive bibliometric analyses in this field are scarce. This study addressed this gap via a systematic bibliometric analysis, retrieving 2013-2025 relevant articles from the Web of Science Core Collection and analyzing them with CiteSpace and VOSviewer. A total of 2,415 articles were included, with annual publications growing exponentially. The United States led in publication volume and citations; the University of Groningen (167 papers) was the top institution, and a mature core-scholar-led research team and collaboration network has formed. Diabetes, Obesity and Metabolism (163 publications) was the most prolific journal. Co-citation analysis identified 7 distinct clusters (autophagy, ketoacidosis, renal growth, finerenone, hypoxia, glomerular filtration rate, sodium-glucose cotransporter 2) and two core directions: drug action mechanisms and clinical treatment strategies. Burst keyword and keyword analyses revealed the research focus shifted from clinical trial design to cardiorenal protective mechanisms, and recently to precision disease management and combination therapies. Future research should strengthen international collaboration, explore SGLT2 inhibitor-mineralocorticoid receptor antagonist synergies, and design innovative clinical trials with region-specific endpoints.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.